• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025

    Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025.

    The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated approach to treasury management, including through the integration of actively managed decentralized finance protocols and Binance ecosystem specific strategies, aimed at enhancing capital efficiency, liquidity resilience, and exposure to digital asset upside.

    No action by the Company's stockholders is required with respect to the ticker symbol change. The Company's common stock will continue to be listed on Nasdaq and the CUSIP number will remain unchanged.

    About Applied DNA Sciences

    Applied DNA Sciences is a biotechnology company executing a yield focused BNB digital asset treasury strategy, while also commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

    Forward Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. Forward-looking statements are statements other than historical facts and address various matters including, without limitation, statements relating to the assets to be held by the Company, the expected future market, price and liquidity of the digital assets the Company acquires, the macro and political conditions surrounding digital assets, the Company's plan for value creation and strategic advantages, market size, market position, and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, future announcements and priorities, expectations regarding management, future financial and operating condition and performance, the expected financial impacts of the proposed transactions described herein and other projections or statements of plans and objectives.

    These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to realize the anticipated benefits of the proposed digital asset treasury strategy; changes in business, market, financial, political and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price of BNB and other cryptocurrencies; risks related to the Company's ability to raise and deploy capital effectively; risks relating to an unproven yield generation strategy, the risk that the price of the Company's common stock may be highly correlated to the price of the digital assets that it holds; risks related to increased competition in the industries in which the Company does and will operate; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; risks related to the unknown returns, liquidity and/or token accumulation that the Company's BNB treasury strategy will generate; risks relating to market volatility, cybersecurity and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting BNB or other digital assets; as well as those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

    Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

    Web: www.adnas.com

    X: APDN

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251006445821/en/

    Investor Relations: John Ragozzino Jr., CFA [email protected]

    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation

    Appoints TradFi and DeFi Leaders as Advisers, Including Anthony Scaramucci Enhanced Staking and Yield Strategy Focused on BNB Native Yield Integrating DeFi and Binance Ecosystem Expertise Offering Led by Institutional and Crypto-Native Investors including Galaxy, Off The Chain, Silvermine and Gaia Digital Assets Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity ("PIPE") offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurren

    9/29/25 3:08:00 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

    - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

    1/10/25 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

    2/11/22 6:29:21 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

    8/13/21 6:30:16 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

    4/22/21 6:37:35 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jantzen Beth

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:56 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Shorrock Clay

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:40 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Murrah Judith

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:30 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    SEC Filings

    View All

    Applied DNA Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    10/6/25 4:06:01 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    10/1/25 10:08:42 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events

    8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    9/29/25 4:01:35 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    View All

    Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

    Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

    9/6/23 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

    STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

    4/1/21 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/13/24 4:15:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/7/24 10:11:34 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

    STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

    12/16/24 10:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

    STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

    8/7/24 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary